The terminated clinical trial, sponsored by the University Hospital of Toulouse, aimed to assess the efficacy of music therapy in reducing the need for neuroleptic medications in Alzheimer's patients with behavioral disturbances. Given the increasing prevalence of Alzheimer's disease and the growing demand for alternative therapies to manage behavioral symptoms, successful outcomes could have positioned music therapy as a viable adjunct treatment, potentially reducing healthcare costs associated with neuroleptic prescriptions. However, the termination of the study raises concerns regarding the feasibility and effectiveness of this approach, necessitating further investigation into alternative non-pharmacological interventions. The market for Alzheimer's treatments is highly competitive, with numerous pharmaceutical and therapeutic options being explored, underscoring the need for robust clinical evidence to support any new treatment modality.